CEPI to co-fund Vaxxinity’s pivotal Phase 3 UB-612 heterologous booster trial to…
OSLO, Norway and DALLAS, April 06, 2022 (GLOBE NEWSWIRE) -- The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity, Inc. (Nasdaq: VAXX), a US company pioneering the…